Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences

Andrea DeCensi, Zhuoxin Sun, Aliana Guerrieri-Gonzaga, Beat Thürlimann, Christina McIntosh, Carlo Tondini, Alain Monnier, Mario Campone, Marc Debled, Astrid Schönenberger, Khalil Zaman, Harriet Johansson, Karen N. Price, Richard D. Gelber, Aron Goldhirsch, Alan S. Coates, Stefan Aebi

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The purpose of the study is to determine the effects of the BIG 1-98 treatments on bone mineral density. BIG 1-98 compared 5-year adjuvant hormone therapy in postmenopausal women allocated to four groups: tamoxifen (T); letrozole (L); 2-years T, 3-years L (TL); and 2-years L, 3-years T (LT). Bone mineral density T-score was measured prospectively annually by dual energy X-ray absorption in 424 patients enrolled in a sub-study after 3 (n = 150), 4 (n = 200), and 5 years (n = 74) from randomization, and 1 year after treatment cessation. Prevalence of osteoporosis and the association of C-telopeptide, osteocalcin, and bone alkaline phosphatase with T-scores were assessed. At 3 years, T had the highest and TL the lowest T-score. All arms except for LT showed a decline up to 5 years, with TL exhibiting the greatest. At 5 years, there were significant differences on lumbar T-score only between T and TL, whereas for femur T-score, differences were significant for T versus L or TL, and L versus LT. The 5-year prevalence of spine and femur osteoporosis was the highest on TL (14.5 %, 7.1 %) then L (4.3 %, 5.1 %), LT (4.2 %, 1.4 %) and T (4 %, 0). C-telopeptide and osteocalcin were significantly associated with T-scores. While adjuvant L increases bone mineral density loss compared with T, the sequence LT has an acceptable bone safety profile. C-telopeptide and osteocalcin are useful markers of bone density that may be used to monitor bone health during treatment. The sequence LT may be a valid treatment option in patients with low and intermediate risk of recurrence.

Original languageEnglish
Pages (from-to)321-329
Number of pages9
JournalBreast Cancer Research and Treatment
Volume144
Issue number2
DOIs
Publication statusPublished - 2014

Fingerprint

letrozole
Tamoxifen
Bone Density
Osteocalcin
Biomarkers
Bone and Bones
Femur
Osteoporosis
Withholding Treatment
Therapeutics
Random Allocation
Alkaline Phosphatase
Spine
X-Rays
Hormones
Safety
Recurrence
Health

Keywords

  • Adjuvant drug therapy
  • Aromatase inhibitor
  • Bone density
  • Bone turnover
  • Breast cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Medicine(all)

Cite this

Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences. / DeCensi, Andrea; Sun, Zhuoxin; Guerrieri-Gonzaga, Aliana; Thürlimann, Beat; McIntosh, Christina; Tondini, Carlo; Monnier, Alain; Campone, Mario; Debled, Marc; Schönenberger, Astrid; Zaman, Khalil; Johansson, Harriet; Price, Karen N.; Gelber, Richard D.; Goldhirsch, Aron; Coates, Alan S.; Aebi, Stefan.

In: Breast Cancer Research and Treatment, Vol. 144, No. 2, 2014, p. 321-329.

Research output: Contribution to journalArticle

DeCensi, A, Sun, Z, Guerrieri-Gonzaga, A, Thürlimann, B, McIntosh, C, Tondini, C, Monnier, A, Campone, M, Debled, M, Schönenberger, A, Zaman, K, Johansson, H, Price, KN, Gelber, RD, Goldhirsch, A, Coates, AS & Aebi, S 2014, 'Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences', Breast Cancer Research and Treatment, vol. 144, no. 2, pp. 321-329. https://doi.org/10.1007/s10549-014-2849-2
DeCensi, Andrea ; Sun, Zhuoxin ; Guerrieri-Gonzaga, Aliana ; Thürlimann, Beat ; McIntosh, Christina ; Tondini, Carlo ; Monnier, Alain ; Campone, Mario ; Debled, Marc ; Schönenberger, Astrid ; Zaman, Khalil ; Johansson, Harriet ; Price, Karen N. ; Gelber, Richard D. ; Goldhirsch, Aron ; Coates, Alan S. ; Aebi, Stefan. / Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences. In: Breast Cancer Research and Treatment. 2014 ; Vol. 144, No. 2. pp. 321-329.
@article{2ea7c9dd9e9047fa84071e9a6eec034c,
title = "Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences",
abstract = "The purpose of the study is to determine the effects of the BIG 1-98 treatments on bone mineral density. BIG 1-98 compared 5-year adjuvant hormone therapy in postmenopausal women allocated to four groups: tamoxifen (T); letrozole (L); 2-years T, 3-years L (TL); and 2-years L, 3-years T (LT). Bone mineral density T-score was measured prospectively annually by dual energy X-ray absorption in 424 patients enrolled in a sub-study after 3 (n = 150), 4 (n = 200), and 5 years (n = 74) from randomization, and 1 year after treatment cessation. Prevalence of osteoporosis and the association of C-telopeptide, osteocalcin, and bone alkaline phosphatase with T-scores were assessed. At 3 years, T had the highest and TL the lowest T-score. All arms except for LT showed a decline up to 5 years, with TL exhibiting the greatest. At 5 years, there were significant differences on lumbar T-score only between T and TL, whereas for femur T-score, differences were significant for T versus L or TL, and L versus LT. The 5-year prevalence of spine and femur osteoporosis was the highest on TL (14.5 {\%}, 7.1 {\%}) then L (4.3 {\%}, 5.1 {\%}), LT (4.2 {\%}, 1.4 {\%}) and T (4 {\%}, 0). C-telopeptide and osteocalcin were significantly associated with T-scores. While adjuvant L increases bone mineral density loss compared with T, the sequence LT has an acceptable bone safety profile. C-telopeptide and osteocalcin are useful markers of bone density that may be used to monitor bone health during treatment. The sequence LT may be a valid treatment option in patients with low and intermediate risk of recurrence.",
keywords = "Adjuvant drug therapy, Aromatase inhibitor, Bone density, Bone turnover, Breast cancer",
author = "Andrea DeCensi and Zhuoxin Sun and Aliana Guerrieri-Gonzaga and Beat Th{\"u}rlimann and Christina McIntosh and Carlo Tondini and Alain Monnier and Mario Campone and Marc Debled and Astrid Sch{\"o}nenberger and Khalil Zaman and Harriet Johansson and Price, {Karen N.} and Gelber, {Richard D.} and Aron Goldhirsch and Coates, {Alan S.} and Stefan Aebi",
year = "2014",
doi = "10.1007/s10549-014-2849-2",
language = "English",
volume = "144",
pages = "321--329",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York LLC",
number = "2",

}

TY - JOUR

T1 - Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences

AU - DeCensi, Andrea

AU - Sun, Zhuoxin

AU - Guerrieri-Gonzaga, Aliana

AU - Thürlimann, Beat

AU - McIntosh, Christina

AU - Tondini, Carlo

AU - Monnier, Alain

AU - Campone, Mario

AU - Debled, Marc

AU - Schönenberger, Astrid

AU - Zaman, Khalil

AU - Johansson, Harriet

AU - Price, Karen N.

AU - Gelber, Richard D.

AU - Goldhirsch, Aron

AU - Coates, Alan S.

AU - Aebi, Stefan

PY - 2014

Y1 - 2014

N2 - The purpose of the study is to determine the effects of the BIG 1-98 treatments on bone mineral density. BIG 1-98 compared 5-year adjuvant hormone therapy in postmenopausal women allocated to four groups: tamoxifen (T); letrozole (L); 2-years T, 3-years L (TL); and 2-years L, 3-years T (LT). Bone mineral density T-score was measured prospectively annually by dual energy X-ray absorption in 424 patients enrolled in a sub-study after 3 (n = 150), 4 (n = 200), and 5 years (n = 74) from randomization, and 1 year after treatment cessation. Prevalence of osteoporosis and the association of C-telopeptide, osteocalcin, and bone alkaline phosphatase with T-scores were assessed. At 3 years, T had the highest and TL the lowest T-score. All arms except for LT showed a decline up to 5 years, with TL exhibiting the greatest. At 5 years, there were significant differences on lumbar T-score only between T and TL, whereas for femur T-score, differences were significant for T versus L or TL, and L versus LT. The 5-year prevalence of spine and femur osteoporosis was the highest on TL (14.5 %, 7.1 %) then L (4.3 %, 5.1 %), LT (4.2 %, 1.4 %) and T (4 %, 0). C-telopeptide and osteocalcin were significantly associated with T-scores. While adjuvant L increases bone mineral density loss compared with T, the sequence LT has an acceptable bone safety profile. C-telopeptide and osteocalcin are useful markers of bone density that may be used to monitor bone health during treatment. The sequence LT may be a valid treatment option in patients with low and intermediate risk of recurrence.

AB - The purpose of the study is to determine the effects of the BIG 1-98 treatments on bone mineral density. BIG 1-98 compared 5-year adjuvant hormone therapy in postmenopausal women allocated to four groups: tamoxifen (T); letrozole (L); 2-years T, 3-years L (TL); and 2-years L, 3-years T (LT). Bone mineral density T-score was measured prospectively annually by dual energy X-ray absorption in 424 patients enrolled in a sub-study after 3 (n = 150), 4 (n = 200), and 5 years (n = 74) from randomization, and 1 year after treatment cessation. Prevalence of osteoporosis and the association of C-telopeptide, osteocalcin, and bone alkaline phosphatase with T-scores were assessed. At 3 years, T had the highest and TL the lowest T-score. All arms except for LT showed a decline up to 5 years, with TL exhibiting the greatest. At 5 years, there were significant differences on lumbar T-score only between T and TL, whereas for femur T-score, differences were significant for T versus L or TL, and L versus LT. The 5-year prevalence of spine and femur osteoporosis was the highest on TL (14.5 %, 7.1 %) then L (4.3 %, 5.1 %), LT (4.2 %, 1.4 %) and T (4 %, 0). C-telopeptide and osteocalcin were significantly associated with T-scores. While adjuvant L increases bone mineral density loss compared with T, the sequence LT has an acceptable bone safety profile. C-telopeptide and osteocalcin are useful markers of bone density that may be used to monitor bone health during treatment. The sequence LT may be a valid treatment option in patients with low and intermediate risk of recurrence.

KW - Adjuvant drug therapy

KW - Aromatase inhibitor

KW - Bone density

KW - Bone turnover

KW - Breast cancer

UR - http://www.scopus.com/inward/record.url?scp=84896546869&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896546869&partnerID=8YFLogxK

U2 - 10.1007/s10549-014-2849-2

DO - 10.1007/s10549-014-2849-2

M3 - Article

C2 - 24487691

AN - SCOPUS:84896546869

VL - 144

SP - 321

EP - 329

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 2

ER -